Beacon Therapeutics Shares Positive Three-Month Results from Phase 2 DAWN Study of laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP) Patients.

IMFINZI® (durvalumab) receives Priority Review status in the US for those with muscle-invasive bladder cancer.

Shanghai Henlius Biotech, has reported that the NMPA has accepted the NDA for its proprietary pertuzumab biosimilar HLX11.

Currently, only three CXCR4 (C-X-C motif chemokine receptor 4) antagonists have been approved globally: Plerixafor, Motixafortide, and Mavorixafor.

Henlius has obtained IND approval from NMPA for a Phase 1b/2 clinical study of its new PD-L1-targeting ADC, HLX43.

Nkarta announces approval for investigator-led study in Myasthenia Gravis and begins enrollment for Ntrust-2.

Denali Therapeutics has dosed the first participant in its Phase 2a trial for the LRRK2 inhibitor BIIB122, targeting Parkinson’s disease linked to LRRK2.

Duality Biologics and BioNTech shared encouraging interim findings for their experimental B7-H3 antibody-drug conjugate BNT324/DB-1311.

Simcha Therapeutics has announced the initiation of two clinical trials evaluating ST-067, their decoy-resistant IL-18, for hematological conditions.

Merck and Ridgeback Biotherapeutics have started a Phase 3 trial (MOVe-NOW) to assess LAGEVRIO™ (molnupiravir) in treating COVID-19 among high-risk adults.

IMFINZI® (durvalumab) has been authorized in the US as the first and sole immunotherapy treatment for patients with limited-stage small cell lung cancer.

Elritercept is an advanced investigational activin inhibitor aimed at treating anemia linked with specific hematologic malignancies.